RxDoctor Payments Data

Mark Silvert, MD

Urology · San Pablo, CANPI 1265533426

Payments from drug & device makers

$2,679in general payments, 2019–2025

Across 102 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$537
  • Astellas Pharma US Inc$466
  • Johnson & Johnson$406
  • Teleflex LLC$153
  • Sanofi$125
  • Pfizer$99
  • plus $894 from 20 others

What the payments were for

  • Food & beverage$2,64499%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,679 in reported general payments places this provider in the 50th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$192,276
Medicare patients
412
Services billed
3,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron122$86,314
Oxybutynin Chloride ErOxybutynin Chloride203$5,701
Tamsulosin Hcl416$5,554
Testosterone Cypionate38$2,312
Bicalutamide60$1,941
Dutasteride19$1,754
Testosterone23$1,700
Solifenacin Succinate22$1,640
Finasteride56$649
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim115$257
Ciprofloxacin Hcl44$166
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$147
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$88
Doxycycline Hyclate11$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$466$86,314122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,324 urology providers in California.

Other urology in San Pablo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →